OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00282655

Tibet Aim Pharm Inc

PharmaceuticalsVerified

Tibet Aim Pharm Inc maintains a strong liquidity position, with a current ratio of 3.22, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt is supported by a positive free cash flow of 79.92 million CNY, which reflects its ability to generate cash after capital expenditures. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. In terms of profitability, Tibet Aim Pharm Inc reports a return on equity (ROE) of 11.35% and a return on assets (ROA) of 9.1%, both of which are strong indicators of efficient capital use and asset management. These metrics suggest the company is performing well relative to its equity and asset base, though direct comparisons to industry medians are not available in the current dataset. The company's revenue is concentrated in a single geographic market, China, as disclosed in its financial segments. There is no indication of revenue diversification across regions or product lines in the available data. This concentration may expose the company to regional economic or regulatory risks, though no specific geopolitical drivers are cited in the industry_config for this sector. Looking ahead, the company's growth trajectory is not explicitly outlined in the input data. However, the positive operating cash flow of 123.72 million CNY and a net income of 92.58 million CNY suggest a stable financial performance. The capital expenditure of -8.496 million CNY indicates a reduction in investment in physical assets, which may signal a shift in strategic focus or a capital conservation strategy. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The low dilution risk is supported by the absence of dilution potential in the basic shares outstanding and the lack of recent equity issuance activity. However, the negative net cash position after subtracting total debt is a notable risk factor that could affect the company's ability to meet long-term obligations. Recent events, such as filings and transcripts, are not detailed in the input data. The company's financial statements and disclosures do not indicate any material events that would significantly alter its current financial or operational outlook.

30-day price · 002826-1.55 (-7.8%)
Low$18.21High$21.66Close$18.40As of15 May, 00:00 UTC
Profile
CompanyTibet Aim Pharm Inc
Ticker002826.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Tibet Aim Pharm Inc is a pharmaceutical company that develops and sells drugs, primarily in the Chinese market.

Classification. Tibet Aim Pharm Inc is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.

Tibet Aim Pharm Inc maintains a strong liquidity position, with a current ratio of 3.22, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt is supported by a positive free cash flow of 79.92 million CNY, which reflects its ability to generate cash after capital expenditures. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. In terms of profitability, Tibet Aim Pharm Inc reports a return on equity (ROE) of 11.35% and a return on assets (ROA) of 9.1%, both of which are strong indicators of efficient capital use and asset management. These metrics suggest the company is performing well relative to its equity and asset base, though direct comparisons to industry medians are not available in the current dataset. The company's revenue is concentrated in a single geographic market, China, as disclosed in its financial segments. There is no indication of revenue diversification across regions or product lines in the available data. This concentration may expose the company to regional economic or regulatory risks, though no specific geopolitical drivers are cited in the industry_config for this sector. Looking ahead, the company's growth trajectory is not explicitly outlined in the input data. However, the positive operating cash flow of 123.72 million CNY and a net income of 92.58 million CNY suggest a stable financial performance. The capital expenditure of -8.496 million CNY indicates a reduction in investment in physical assets, which may signal a shift in strategic focus or a capital conservation strategy. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The low dilution risk is supported by the absence of dilution potential in the basic shares outstanding and the lack of recent equity issuance activity. However, the negative net cash position after subtracting total debt is a notable risk factor that could affect the company's ability to meet long-term obligations. Recent events, such as filings and transcripts, are not detailed in the input data. The company's financial statements and disclosures do not indicate any material events that would significantly alter its current financial or operational outlook.
Key takeaways
  • Tibet Aim Pharm Inc has a strong liquidity position with a current ratio of 3.22 and a positive free cash flow of 79.92 million CNY.
  • The company's ROE of 11.35% and ROA of 9.1% indicate efficient use of equity and assets.
  • Revenue is concentrated in a single geographic market, China, which may expose the company to regional risks.
  • The company has a low dilution risk and no recent equity issuance activity.
  • The negative net cash position after subtracting total debt is a key liquidity flag.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$636.3M
Gross profit$522.5M
Operating income$100.6M
Net income$92.6M
R&D
SG&A
D&A
SBC
Operating cash flow$123.7M
CapEx-$8.5M
Free cash flow$79.9M
Total assets$1.02B
Total liabilities$201.7M
Total equity$816.0M
Cash & equivalents
Long-term debt$11.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$636.3M$100.6M$92.6M$79.9M
FY-1$651.9M$61.3M$45.9M$50.9M
FY-2$667.0M$23.4M$15.4M$16.4M
FY-3$856.7M$55.7M$44.1M$45.9M
FY-4$725.5M$48.6M$42.5M$25.9M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$1.02B$816.0M
FY-1$926.5M$739.0M
FY-2$927.7M$745.0M
FY-3$1.02B$745.3M
FY-4$824.5M$717.4M
PeriodOCFCapExFCFSBC
FY0$123.7M-$8.5M$79.9M
FY-1$111.6M-$12.2M$50.9M
FY-2$166.9M-$3.2M$16.4M
FY-3$68.5M-$3.2M$45.9M
FY-4$109.5M-$25.2M$25.9M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$182.6M$24.9M$19.6M
FQ-1$147.3M$11.3M$10.8M
FQ-2$177.5M$38.6M$44.2M
FQ-3$162.9M$29.6M$18.8M
FQ-4$148.5M$21.1M$18.8M
FQ-5$139.0M$10.3M$4.1M
FQ-6$160.9M$4.8M$2.2M
FQ-7$191.6M$14.0M$11.7M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$1.10B$838.0M$433.6M
FQ-1$1.02B$816.0M
FQ-2$1.06B$802.1M$297.7M
FQ-3$1.01B$764.0M
FQ-4$986.5M$760.8M$292.5M
FQ-5$926.5M$739.0M
FQ-6$953.5M$732.9M$227.9M
FQ-7$923.7M$730.9M
PeriodOCFCapExFCFSBC
FQ0$79.4M-$818.1k
FQ-1$123.7M-$8.5M
FQ-2$149.6M-$5.5M
FQ-3$62.5M-$2.5M
FQ-4$30.9M-$479.2k
FQ-5$111.6M-$12.2M
FQ-6$113.8M-$9.4M
FQ-7$46.1M-$8.1M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$816.0M
Net cash-$11.3M
Current ratio3.2
Debt/Equity0.0
ROA9.1%
ROE11.3%
Cash conversion1.3%
CapEx/Revenue-1.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric002826Activity
Op margin15.8%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin14.6%14.7% medp25 11.7% · p75 28.1%below median
Gross margin82.1%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-1.3%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity1.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-18 00:11 UTCJob: b0fd925d